How to learn from interval cancers in colorectal cancer screening

Endoscopy 2024; 56(05): 373-375
DOI: 10.1055/a-2279-9932

Editorial

Referring to Wisse PHA et al. doi: 10.1055/a-2230-5563

Michael Bretthauer

¹Clinical Effectiveness Research Group and Department of Transplantation Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway

References
1 Wisse PHA, de Boer SY, Oudkerk Pool M. et al. Post-colonoscopy colorectal cancers in a national fecal immunochemical test-based colorectal cancer screening program. Endoscopy 2024;
2 Rutter MD, Beintaris I, Valori R. et al. World Endoscopy Organization Consensus Statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology 2018; 155: 909-925.e903
3 Burr NE, Derbyshire E, Taylor J. et al. Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study. BMJ 2019; 367: l6090
4 Jodal HC, Løberg M, Holme Ø. et al. Mortality from postscreening (interval) colorectal cancers is comparable to that from cancer in unscreened patients-a randomized sigmoidoscopy trial. Gastroenterology 2018; 155: 1787-1794.e3
5 Bowles CJ, Leicester R, Romaya C. et al. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow?. Gut 2004; 53: 277-283
6 Performance measures for lower gastrointestinal endoscopy. a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
7 Singh G, Patel RH, Boster J. Root cause analysis and medical error prevention. [Updated 2023 May 30]. Treasure Island, Florida: StatPearls Publishing; 2024. Accessed March 01, 2024 at: https://www.statpearls.com/point-of-care/131252